Released Mar 17, 2021, after the close
10-K filed Mar 18, 2021, 77 days after period end · 0001564590-21-013945
Q4 2020 · 10-K
Revenue$8.28M$8.28M −26.8% vs Q4 2019−53.6% vs Q3 2020
Net Income-$59.54M-$59.54M N/M vs Q4 2019N/M vs Q3 2020
EPS Diluted-$1.48-$1.48 N/M vs Q4 2019N/M vs Q3 2020
Operating Incomederived-$24,843,000N/M
Operating Cash Flowderived-$18,879,000N/M
Margins · derived
Operating margin-300.1%−169.4 pt vs Q4 2019
Net margin-719.3%−588.5 pt vs Q4 2019
What the release said
The release
Same quarter
| Metric | Q4 2020 | Q4 2019 | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Revenue | $8.28M | $11.31M | $19.09M | $4.04M |
| Net Income | -$59.54M | -$14.79M | -$1.49M | -$15.34M |
| EPS Diluted | -$1.48 | -$0.65 | -$0.07 | -$33.51 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR